Abstract:Object: Sertraline is a first-line SSRI for the treatment of depression and has the same effectiveness along with a superior safety profile compared to other medications. There are few population pharmacokinetic (PPK) studies of sertraline and a lack of studies in the Chinese population. Therefore, we performed a PPK analysis of Chinese patients treated with sertraline to identify factors that can influence drug exposure. In addition, the dosing and discontinuation regimen of sertraline when applied to adolescents was explored. Methods: Sertraline serum drug concentration data were collected from 140 hospitalized patients to generate a sertraline PPK dataset, and data evaluation and examination of the effects of covariates on drug exposure in the final model were performed using nonlinear mixed-effects models (NONMEM) and first-order conditional estimation with interaction (FOCE-I). Examining rational medication administration and rational withdrawal of sertraline based on significant covariates and final modeling. Results: A one-compartment model with first-order absorption and elimination of sertraline was developed for Chinese patients with psychiatric disorders. Analysis of covariates revealed that age was a covariate that significantly affected sertraline CL/F (P < 0.01) and that sertraline clearance decreased progressively with aging, whereas other factors had no effect on CL/F and V/F of sertraline. In the age range of 11-79, there were 54 adolescent patients (about 1/3) aged 13-18 years, and the safe and effective optimal daily dose for adolescent patients based on the final model simulations was 50-250 mg/d. For adolescent patients, serum concentration fluctuations were moderate for OD doses of 50 mg and 100 mg, using a fixed dose-descent regimen. For patients with OD doses of 150-200 mg and BID doses of 100-200 mg, a more gradual decrease in serum concentration was achieved with a fixed dose interval of 7 or 14 days for 25 mg as the regimen of descent. Conclusions: To our knowledge, this may be the first PPK study of sertraline in Chinese patients. We found that age was an important factor affecting clearance in Chinese patients taking sertraline. Patients taking sertraline may be exposed to increased amounts of sertraline due to decreased clearance with increasing age. The rational dosing and safe discontinuation of sertraline in adolescent patients can be appropriately referenced to the results of the model simulation, thus providing assistance for individualized dosing in adolescents.

Population pharmacokinetic modeling of quetiapine after administration of SEROQUEL and SEROQUEL XR formulations to western and Chinese patients with schizophrenia, schizoaffective disorder or bipolar disorder.

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients

Bioequivalence of Two Quetiapine Extended Release Tablets in Chinese Healthy Volunteers under Fasting and Fed Conditions and Effects of Food on Pharmacokinetic Profiles.

Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia

A 6-Week, Multicenter, Double-Blind, Double-Dummy, Chlorpromazine-Controlled Non-Inferiorityrandomized Phase Iiitrial to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) in the Treatment of Patients with Schizophrenia and Acute Episodes.

Pharmacokinetic Prediction of Immediate- and Extended-Release Tablets for Patients with Liver Disease Using Whole Body Physiologically-Based Pharmacokinetic Modeling for the Antipsychotic Drug Quetiapine

Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

Metabolic Mechanism of Quetiapine at Clinical Therapeutic Dose in Vivo

Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients

EFFICACY AND TOLERABILITY OF QUETIAPINE XR 400/600/800MG/DAY IN ACUTE SCHIZOPHRENIA: A POST-HOC ANALYSIS OF DATA FROM TWO POOLED RANDOMISED STUDIES

Development of a Population Pharmacokinetic Model of Olanzapine for Chinese Health Volunteers and Patients with Schizophrenia.

Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis

Comparisons of the Tolerability and Sensitivity of Quetiapine-Xr in the Acute Treatment of Schizophrenia, Bipolar Mania, Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder

Population Pharmacokinetics of Amisulpride in Chinese Patients with Schizophrenia with External Validation: the Impact of Renal Function.

Population Pharmacokinetic-Pharmacodynamic (poppk/pd) Modeling of Risperidone and Its Active Metabolite in Chinese Schizophrenia Patients.

Clinical study of quetiapine and clozapine in the treatment of schizophrenia

Population Pharmacokinetics Of Zonisamide After Oral Administration In Healthy Chinese Volunteers

Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.

Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats